Effects of Reinjected Monoclonal Antibody against the Platelet Glycoprotein IIb/IIIa Complex into Monkeys
スポンサーリンク
概要
- 論文の詳細を見る
We previously reported that our monoclonal antibody, NNKY1-32, which recognizes the human platelet glycoprotein (GP) IIb/IIIa complex, suppressed monkey platelet function both in vitro and in vivo. To assess the effects of the reinjected antibody, we administered two doses of intravenous NNKY1-32 into Japanese monkeys.The second injection of NNKY1-32 IgG produced anti-mouse IgG antibodies in all of the monkeys. In two of four monkeys reinjected with NNKY1-32 IgG, platelet count was remarkably decreased. In addition, the NNKY1-32 IgG induced platelet aggregation in platelet rich plasma obtained from these monkeys. This suggests that the observed aggregation was related to both monkey anti-mouse IgG antibody and NNKY1-32 IgG fragments. Two other monkeys showed only modest fluctuations in platelet count, and the IgG fractions obtained from these monkeys abolished the suppression of platelet aggregation by NNKY1-32.In contrast, the second injection of NNKY1-32 Fab fragments did not produce antimouse Fab antibody nor reduce platelet count. Suppression of ADP-induced platelet aggregation was comparable to that seen after the first injection.These results indicate that the IgG of mouse monoclonal antibody has potent in vivo antigenicity as compared with that of Fab fragments, and that the anti-mouse IgG antibody produced in monkeys may induce monkey platelet aggregation in vivo in association with the injected monoclonal antibody.
- 一般社団法人 日本血栓止血学会の論文
一般社団法人 日本血栓止血学会 | 論文
- 日本人のＡＤＡＭＴＳ１３
- Infection of specific strains of Streptococcus mutans exacerbated intracerebral hemorrhage
- Transcriptional regulation of megakaryopoiesis and thrombopoiesis
- 新規血小板活性化受容体ＣＬＥＣ－２ その発見から今後の展望まで:その発見から今後の展望まで
- １．臨床血栓止血学オーバービュー